Skip to content
DataLookout
Menu

NCT07310485

Examining the Impact of Phytoestrogens Supplementation on the Gene Expression, and Premenstrual Syndrome in Primenopausal Women

StatusCompleted
PhaseNot applicable
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Start date pushed from Nov 1, 2025 to Feb 1, 2026 Show 4 more changesShow less
    • Eligibility criteria expanded, about 11 words
    • Trial status changed: Enrolling by Invitation → Completed
    • Study completion date changed from estimate of Aug 31, 2026 to May 25, 2026
    • Secondary endpoints: details revised at 3 of 3 entries
  2. Notable Primary endpoint(s) modifiedv2 Show 6 more changesShow less
    • Eligibility criteria expanded, about 9 words
    • Enrollment reduced: 70 → 50 participants
    • Primary completion date changed from estimate of Jan 2, 2026 to May 25, 2026
    • Study completion pushed from Feb 20, 2026 to Aug 31, 2026
    • Secondary endpoints: 1 to 3
    • Study description shortened, about 6 words
  3. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Fold Change From Baseline in FSTL1 Gene Expression
Timeframe: Time Frame: Baseline (Week 0) and End of Intervention (Week 12)
Fold Change From Baseline in TGFB1 Gene Expression
Timeframe: (Week 0) and end of intervention (Week 12)

Secondary (3)

Change From Baseline in the Mean Physical-Symptom Domain Score on the Arabic Premenstrual Syndrome Scale
Change From Baseline in the Mean Psychological-Symptom Domain Score on the Arabic Premenstrual Syndrome Scale
Change From Baseline in the Impairment-of-Functioning Domain Score on the Arabic Premenstrual Syndrome Scale

Arms and interventions

placeboPlacebo comparator

Microcrystalline cellulose (Placebo), taken orally once daily for 12 weeks. The capsule is matched in size, color, and taste to the active phytoestrogen supplement.

Intevention SDG lignansExperimental

Dietary Supplement: SDG lignans phytoestrogen 100 mg SDG (Active Ingredient), taken orally once daily for 12 weeks

Dietary supplements: SDG lignans, Placebo

Sites

1 site in 1 country

  • the university of JordanAmman, Amman Governorate, Jordan